WallStreetZenWallStreetZen

NASDAQ: RENB
Renovaro Biosciences Inc Stock

$3.23-0.20 (-5.83%)
Updated Nov 28, 2023
RENB Price
$3.23
Fair Value Price
$3.28
Market Cap
$215.44M
52 Week Low
$0.39
52 Week High
$5.25
P/E
-4.55x
P/B
4.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$41.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$12M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

RENB Overview

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RENB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RENB ($3.23) is undervalued by 1.6% relative to our estimate of its Fair Value price of $3.28 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RENB ($3.23) is not significantly undervalued (1.6%) relative to our estimate of its Fair Value price of $3.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RENB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RENB due diligence checks available for Premium users.

Be the first to know about important RENB news, forecast changes, insider trades & much more!

RENB News

Valuation

RENB fair value

Fair Value of RENB stock based on Discounted Cash Flow (DCF)
Price
$3.23
Fair Value
$3.28
Undervalued by
1.60%
RENB ($3.23) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RENB ($3.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RENB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RENB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.55x
Industry
12.55x
Market
32.56x

RENB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.61x
Industry
5.31x
RENB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RENB's financial health

Profit margin

Revenue
$0.0
Net Income
-$9.2M
Profit Margin
0%
RENB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$57.6M
Liabilities
$10.8M
Debt to equity
0.23
RENB's short-term liabilities ($10.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RENB's short-term assets ($1.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RENB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RENB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.8M
Investing
-$1.1M
Financing
$2.6M
RENB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RENB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RENB$215.44M-5.83%-4.55x4.61x
EYPT$215.03M-0.98%-2.29x3.67x
CDT$214.80M+29.39%-0.00x-198.71x
CMPX$214.18M+2.44%-5.09x1.34x
OVID$214.16M-6.19%-4.39x2.11x

Renovaro Biosciences Stock FAQ

What is Renovaro Biosciences's quote symbol?

(NASDAQ: RENB) Renovaro Biosciences trades on the NASDAQ under the ticker symbol RENB. Renovaro Biosciences stock quotes can also be displayed as NASDAQ: RENB.

If you're new to stock investing, here's how to buy Renovaro Biosciences stock.

What is the 52 week high and low for Renovaro Biosciences (NASDAQ: RENB)?

(NASDAQ: RENB) Renovaro Biosciences's 52-week high was $5.25, and its 52-week low was $0.39. It is currently -38.48% from its 52-week high and 721.88% from its 52-week low.

How much is Renovaro Biosciences stock worth today?

(NASDAQ: RENB) Renovaro Biosciences currently has 66,698,144 outstanding shares. With Renovaro Biosciences stock trading at $3.23 per share, the total value of Renovaro Biosciences stock (market capitalization) is $215.44M.

Renovaro Biosciences stock was originally listed at a price of $6.97 in Dec 11, 2018. If you had invested in Renovaro Biosciences stock at $6.97, your return over the last 4 years would have been -53.63%, for an annualized return of -17.48% (not including any dividends or dividend reinvestments).

How much is Renovaro Biosciences's stock price per share?

(NASDAQ: RENB) Renovaro Biosciences stock price per share is $3.23 today (as of Nov 28, 2023).

What is Renovaro Biosciences's Market Cap?

(NASDAQ: RENB) Renovaro Biosciences's market cap is $215.44M, as of Nov 30, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Renovaro Biosciences's market cap is calculated by multiplying RENB's current stock price of $3.23 by RENB's total outstanding shares of 66,698,144.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.